Yanushi Dullewe Wijeyeratne

Yanushi Dullewe Wijeyeratne

Auto-generated profile, based on publicly available information

Yanushi Dullewe Wijeyeratne

Cardiovascular Research Institute, City St George’s University of London

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in JACC
Verified
Journal Article
Open access
NLNajim Lahrouchi
Najim Lahrouchi
HRHariharan Raju
Hariharan Raju
ELElisabeth M. Lodder
Elisabeth M. Lodder
EPEfstathios C Papatheodorou
Efstathios C Papatheodorou
JWJames S. Ware
James S. Ware
EBElijah R. Behr
Elijah R. Behr
Sudden arrhythmic death syndrome (SADS) describes a sudden death with negative autopsy and toxicological analysis. Cardiac genetic disease is a likely etiology. This study investigated the clinical utility and combined yield of post-mortem genetic testing (molecular autopsy) in cases of SADS and comprehensive clinical evaluation of surviving relatives. We evaluated 302 expertly validated SADS cases with suitable DNA (median age: 24 years; 65% males) who underwent next-generation sequencing using an extended panel of 77 primary electrical disorder and cardiomyopathy genes. Pathogenic and likely pathogenic variants were classified using American College of Medical Genetics (ACMG) consensus guidelines. The yield of combined molecular autopsy and clinical evaluation in 82 surviving families was evaluated. A gene-level rare variant association analysis was conducted in SADS cases versus controls. A clinically actionable pathogenic or likely pathogenic variant was identified in 40 of 302 cases (13%). The main etiologies established were catecholaminergic polymorphic ventricular tachycardia and long QT syndrome (17 [6%] and 11 [4%], respectively). Gene-based rare variants association analysis showed enrichment of rare predicted deleterious variants in RYR2 (p = 5 × 10-5). Combining molecular autopsy with clinical evaluation in surviving families increased diagnostic yield from 26% to 39%. Molecular autopsy for electrical disorder and cardiomyopathy genes, using ACMG guidelines for variant classification, identified a modest but realistic yield in SADS. Our data highlighted the predominant role of catecholaminergic polymorphic ventricular tachycardia and long QT syndrome, especially the RYR2 gene, as well as the minimal yield from other genes. Furthermore, we showed the enhanced utility of combined clinical and genetic evaluation.

9 September 2011 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
YWYanushi Dullewe Wijeyeratne
Yanushi Dullewe Wijeyeratne
SHStan Heptinstall
Stan Heptinstall
The P2Y12receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both haemostasis and thrombosis. Agents that act as antagonists at this receptor are thus likely to provide effective antithrombotic therapy, provided that there are no adverse effects on haemostasis. Here we describe the ADP receptor antagonists that are available and in development. We also consider their mode of action and ask whether there are additional mechanisms through which they exert their inhibitory effects on platelet function.

1 October 2018 in Heart Rhythm
Verified
Journal Article
Closed access
AMAnat Milman
Anat Milman
JGJean-Baptiste Gourraud
Jean-Baptiste Gourraud
AAAntoine Andorin
Antoine Andorin
PPPieter G. Postema
Pieter G. Postema
FSFrederic Sacher
Frederic Sacher
BBBernard Belhassen
Bernard Belhassen

1 September 2018 in Heart Rhythm
Verified
Journal Article
Closed access
YMYoav Michowitz
Yoav Michowitz
AMAnat Milman
Anat Milman
GSGeorgia Sarquella-Brugada
Georgia Sarquella-Brugada
AAAntoine Andorin
Antoine Andorin
JCJean Champagne
Jean Champagne
BBBernard Belhassen
Bernard Belhassen

1 December 2017 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
AMAnat Milman
Anat Milman
AAAntoine Andorin
Antoine Andorin
JGJean-Baptiste Gourraud
Jean-Baptiste Gourraud
FSFrederic Sacher
Frederic Sacher
PMPhilippe Mabo
Philippe Mabo
BBBernard Belhassen
Bernard Belhassen
Background: Data on the age at first arrhythmic event (AE) in Brugada syndrome are from limited patient cohorts. The aim of this study is 2-fold: (1) to define the age at first AE in a large cohort of patients with Brugada syndrome, and (2) to assess the influence of the mode of AE documentation, sex, and ethnicity on the age at first AE. Methods and Results: A survey of 23 centers from 10 Western and 4 Asian countries gathered data from 678 patients with Brugada syndrome (91.3% men) with first AE documented at time of aborted cardiac arrest (group A, n=426) or after prophylactic implantable cardioverter–defibrillator implantation (group B, n=252). The vast majority (94.2%) of the patients were 16 to 70 years old at the time of AE, whereas pediatric (70 years) comprised 4.3% and 1.5%, respectively. Peak AE rate occurred between 38 and 48 years (mean, 41.9±14.8; range, 0.27–84 years). Group A patients were younger than in Group B by a mean of 6.7 years (46.1±13.2 versus 39.4±15.0 years; P <0.001). In adult patients (≥16 years), women experienced AE 6.5 years later than men ( P =0.003). Whites and Asians exhibited their AE at the same median age (43 years). Conclusions: SABRUS (Survey on Arrhythmic Events in Brugada Syndrome) presents the first analysis on the age distribution of AE in Brugada syndrome, suggesting 2 age cutoffs (16 and 70 years) that might be important for decision-making. It also allows gaining insights on the influence of mode of arrhythmia documentation, patient sex, and ethnic origin on the age at AE.

1 May 2018 in Heart Rhythm
Verified
Journal Article
Closed access
AMAnat Milman
Anat Milman
AAAntoine Andorin
Antoine Andorin
JGJean-Baptiste Gourraud
Jean-Baptiste Gourraud
PPPieter G. Postema
Pieter G. Postema
FSFrederic Sacher
Frederic Sacher
BBBernard Belhassen
Bernard Belhassen